SCHEMBL830346

SCHEMBL830346

O=C(Oc1cc2ccccc2cn1)N1CCN(c2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.53
ALOX15 P16050 1/20 0.52
TSHR P16473 7/20 0.50
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 5/20 0.49
ALDH1A1 P00352 5/20 0.49
MAPK1 P28482 4/20 0.49
CYP3A4 P08684 3/20 0.49
TP53 P04637 1/20 0.49
HTR1A P08908 1/20 0.46
HTR2A P28223 1/20 0.46
DRD3 P35462 1/20 0.46
MAPT P10636 4/20 0.45
CYP2C19 P33261 2/20 0.45
CYP1A2 P05177 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CYP2C9 P11712 2/20 0.45
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829013 0.85 SMN1; SMN2 (0.50) LMNASMN1; SMN2ALDH1A1CYP3A4TP53
SCHEMBL830008 0.84 HTR3A (0.50) TSHRALDH1A1HTR1ANPC1GAA
SCHEMBL829632 0.84 POLB (0.53) TSHRLMNASMN1; SMN2ALDH1A1CYP3A4
SCHEMBL829568 0.80 GAA (0.60) TSHRLMNASMN1; SMN2ALDH1A1MAPK1
SCHEMBL829365 0.77 LIPE (0.59) FAAHALDH1A1MEN1KMT2A
SCHEMBL829334 0.76 LIPE (0.56) TSHRSMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL830018 0.74 LMNA (0.45) TSHRLMNAMAPTRAB9ANPSR1
SCHEMBL7175076 0.74 CYP1A2 (0.42) ALDH1A1MAPTCYP1A2NPC1RAB9A
Water SCHEMBL6036774 0.73 CYP1A2 (0.41) ALDH1A1MAPTCYP1A2NPC1RAB9A
SCHEMBL8844981 0.72 ALOX15 (0.72) FAAHALOX15TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US claimed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 FAAH 3046/4885ALOX15 1731/4885TSHR 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.